EMVision Medical Devices (EMV) investor relations material

Company overview and technology

• Developing portable, non-ionizing brain scanners for stroke and traumatic brain injury, targeting both in-hospital and pre-hospital markets.

• Devices address unmet clinical needs by enabling rapid neurodiagnostics at the point of care.

• Over AUD 60 million invested in R&D and commercialization since 2017.

• Supported by industry partnerships, including Keysight Technologies and the Australian Stroke Alliance.

• Management and insiders own about 20% of the company.

Clinical need and market opportunity

• Stroke is a leading cause of death and disability, with incidence expected to nearly double by 2050.

• U.S. sees over 800,000 strokes annually, costing more than $50 billion.

• Timely diagnosis is critical, but many patients miss treatment windows due to delays.

• Devices complement CT/MRI by filling gaps in care pathways, especially where traditional imaging is impractical.

• Addressable U.S. market for emu device sales exceeds $500 million, with even larger potential for the First Responder.

Product features and clinical validation

• Devices use ultra-high frequency radio signals and AI algorithms to detect and classify stroke types in minutes.

• Multi-site Australian study showed 92% sensitivity/85% specificity for hemorrhagic and 95%/80% for ischemic strokes.

• Capable of detecting very small strokes, outperforming previous mobile neuroimaging attempts.

• Technology protected by a comprehensive IP portfolio.